Medpace Holdings, Inc. (MEDP) Operating Margin: 21.02%
Is Medpace Holdings, Inc.’s operating margin high or low?
Medpace Holdings, Inc.'s operating margin of 21.02% is in line with its 5-year average of 19.12%, near the high end of its 5-year range (17.39%–21.19%).
As of Wednesday, June 17, 2026. 0.69% below its 12-month average of 21.16%.
MEDP Operating Margin Chart
MEDP Average Operating Margin Chart
MEDP Current vs Average Operating Margin Chart
MEDP Operating Margin Metrics
OPERATING MARGIN
21.02%
OPERATING MARGIN AVG TTM
21.16%
OPERATING MARGIN AVG 3Y
19.82%
OPERATING MARGIN AVG 5Y
19.12%
OPERATING MARGIN AVG 10Y
16.08%
OPERATING MARGIN AVG 15Y
N/A
OPERATING MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.69%
CURRENT VS 3Y AVG
+6.05%
CURRENT VS 5Y AVG
+9.95%
CURRENT VS 10Y AVG
+30.72%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
MEDP Competitors' Operating Margin
| NAME | MARKET CAP | OPERATING MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | $13.05B | 21.02% | 21.16% | 19.82% | 19.12% |
| Solventum Corporation (SOLV)vs › | $12.91B | 25.54% | 19.38% | 20.05% | 20.47% |
| Align Technology, Inc. (ALGN)vs › | $12.86B | 14.44% | 15.23% | 16.08% | 17.45% |
| The Cooper Companies, Inc. (COO)vs › | $12.69B | 11.77% | 17.41% | 16.25% | 15.86% |
| DaVita Inc. (DVA)vs › | $13.46B | 15.01% | 15.52% | 13.94% | 14.32% |
| Revvity, Inc. (RVTY)vs › | $10.91B | 12.41% | 13.70% | 16.38% | 21.25% |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | -2.02% | -7.24% | -2.92% | -1.15% |
| Baxter International Inc. (BAX)vs › | $10.19B | -2.65% | -1.31% | -6.02% | 0.15% |
| Hologic, Inc. (HOLX)vs › | $16.97B | 17.49% | 19.66% | 22.41% | 27.16% |
| Charles River Laboratories International, Inc. (CRL)vs › | $8.90B | 11.77% | 9.13% | 12.39% | 13.51% |
Operating Efficiency
Gross Margin
29.1%
Operating Margin
21.0%
Medpace Holdings, Inc. Operating Margin Formula & Definition
Operating Margin = Operating Income / Revenue
Operating margin is the percentage of revenue remaining after operating expenses, reflecting operating efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medpace Holdings, Inc. Operating Margin FAQ
- What is the operating margin for Medpace Holdings, Inc. (MEDP)?
- The operating margin for MEDP stock is 21.02%.
- Is Medpace Holdings, Inc.'s operating margin high or low?
- Medpace Holdings, Inc.'s operating margin of 21.02% is in line with its 5-year average of 19.12%, near the high end of its 5-year range (17.39%–21.19%).
- What is the TTM average operating margin for Medpace Holdings, Inc. (MEDP)?
- The TTM average operating margin for MEDP stock is 21.16%.
- What is the 3Y average operating margin for Medpace Holdings, Inc. (MEDP)?
- The 3Y average operating margin for MEDP stock is 19.82%.
- What is the 5Y average operating margin for Medpace Holdings, Inc. (MEDP)?
- The 5Y average operating margin for MEDP stock is 19.12%.
- What is the 10Y average operating margin for Medpace Holdings, Inc. (MEDP)?
- The 10Y average operating margin for MEDP stock is 16.08%.
Medpace Holdings, Inc. Operating Margin History
| DATE | OPERATING MARGIN |
|---|---|
| 2025-12-31 | 21.14% |
| 2024-12-31 | 21.19% |
| 2023-12-31 | 17.86% |
| 2022-12-31 | 19.09% |
| 2021-12-31 | 17.39% |
| 2020-12-31 | 18.04% |
| 2019-12-31 | 14.78% |
| 2018-12-31 | 14.34% |
| 2017-12-31 | 14.87% |
| 2016-12-31 | 12.45% |
| 2015-12-31 | 5.73% |
| 2014-12-31 | 8.96% |
| 2013-12-31 | 21.57% |
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle